Chronic Therapy with Nipradilol,a β-Adrenergic Blocker,Attenuated Left Ventricular Remodeling Following Myocardial Infarction in Rats

• Sonoki Hiroyuki

  Tokyo Research Laboratories, Kowa Co., Ltd.

• Nakamura Masaki

  Tokyo Research Laboratories, Kowa Co., Ltd.

• Takeshita Akira

  Research Institute of Angiocardiology and Cardiovascular Clinic, Faculty of Medicine, Kyushu University

書誌事項

タイトル別名

• Chronic Therapy with Nipradilol, a .BETA.-Adrenergic Blocker, Attenuated Left Ventricular Remodeling Following Myocardial Infarction in Rats.
• Chronic Therapy with Nipradilol a ベータ A

抄録

We determined whether chronic treatment with nipradilol, a β-blocker with vasodilating action, reduces left ventricular cavity dilation (LV remodeling) following myocardial infarction and improves cardiac performance. Myocardial infarction was produced by coronary artery ligation in 16-week-old female rats and then the rats were treated for 3-4 months with nipradilol (10 mg/kg/day) or vehicle (0.5% carboxymethylcellulose). The effect of nipradilol on LV remodeling was evaluated by assessing the left ventricular end-diastolic volume index (LVEDVI)and passive pressure-volume relation curve. Since LVEDVI depends on the infarct size, LVEDVI was compared between the vehicle and nipradilol-treated rats with similar infarct size (10-40%). At 3-4 months after myocardial infarct production, the left ventricular end-diastolic volume index in the vehicle-treated rats with myocardial infarction was significantly increased, compared with that in the sham-operated rats without infarction. The nipradilol-treated rats had a significantly smaller left ventricular volume index than the vehicle-treated rats (2.04±0.16 ml/kg in the vehicle-treated group vs 1.36±0.10 ml/kg in the nipradilol-treated group, P<0.01). The maximum cardiac index achieved by volume loading as an index of cardiac performance was significantly greater in the nipradilol group than the vehicle group (254.5 ± 12.6 ml/min kg in the vehicle group vs 347.9 ± 20.2 ml/min kg in the nipradilol group, P <0.01). These results suggest that chronic treatment of nipradilol attenuated left ventricular cavity dilation after myocardial infarction and improved cardiac performance.

収録刊行物

• Jpn.J.Pharmacol.

  Jpn.J.Pharmacol. 74 (2), 171-178, 1997

  公益社団法人 日本薬理学会

キーワード

• Remodeling
• Myocardial infarction
• Cardiac function
• Nipradilol
• Left ventricular diastolic volume

詳細情報

• CRID: 1390282679263001472
• NII論文ID: 10008678904
• NII書誌ID: AA00691188
• DOI: 10.1254/jjp.74.171
• COI: 1:CAS:528:DyaK2sXktVOgsbk%3D
• ISSN: 13473506
• ISSN: 00215198
• ISSN: http://id.crossref.org/issn/00215198
• NDL書誌ID: 4260346
• PubMed: 9243325
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I4260346
• Web Site: https://search.jamas.or.jp/link/ui/1997242403
• 本文言語コード: en
• データソース種別:
  • JaLC
  • NDL
  • Crossref
  • PubMed
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可